CD274 and non-small cell lung carcinoma: The emergence of immune checkpoint inhibitors (ICIs), specifically antibodies targeting the PD-1/PD-L1 axis, has reshaped the treatment landscape for various cancers including non-small cell lung cancer (NSCLC).